STOCK TITAN

[Form 4] Insmed, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider Trading Alert: Roger Adsett, Chief Operating Officer of Insmed, executed significant stock sales on June 16, 2025, through a pre-planned 10b5-1 trading arrangement established on March 4, 2025.

Transaction Details:

  • First transaction: Sold 6,500 shares at weighted average price of $98.50 (range: $97.93-$98.92)
  • Second transaction: Sold 4,186 shares at weighted average price of $99.32 (range: $98.94-$99.83)
  • Total shares disposed: 10,686 shares
  • Remaining holdings: 130,637 shares held directly

The transactions were executed under a Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by establishing predetermined trading parameters. All shares are held in direct ownership form.

Avviso di Insider Trading: Roger Adsett, Chief Operating Officer di Insmed, ha effettuato vendite significative di azioni il 16 giugno 2025, tramite un piano di trading 10b5-1 predefinito stabilito il 4 marzo 2025.

Dettagli della transazione:

  • Prima transazione: Vendute 6.500 azioni a un prezzo medio ponderato di 98,50 $ (intervallo: 97,93 $-98,92 $)
  • Seconda transazione: Vendute 4.186 azioni a un prezzo medio ponderato di 99,32 $ (intervallo: 98,94 $-99,83 $)
  • Totale azioni cedute: 10.686 azioni
  • Azioni rimanenti: 130.637 azioni detenute direttamente

Le operazioni sono state eseguite nell'ambito di un piano di trading conforme alla Regola 10b5-1, che garantisce una protezione legale contro accuse di insider trading definendo parametri di trading predefiniti. Tutte le azioni sono detenute in forma di proprietà diretta.

Alerta de Operaciones con Información Privilegiada: Roger Adsett, Director de Operaciones de Insmed, realizó ventas significativas de acciones el 16 de junio de 2025, a través de un plan de negociación 10b5-1 preestablecido el 4 de marzo de 2025.

Detalles de la transacción:

  • Primera transacción: Vendió 6,500 acciones a un precio promedio ponderado de $98.50 (rango: $97.93-$98.92)
  • Segunda transacción: Vendió 4,186 acciones a un precio promedio ponderado de $99.32 (rango: $98.94-$99.83)
  • Total de acciones vendidas: 10,686 acciones
  • Acciones restantes: 130,637 acciones en propiedad directa

Las transacciones se ejecutaron bajo un plan de negociación conforme a la Regla 10b5-1, que ofrece una protección legal contra acusaciones de uso de información privilegiada mediante el establecimiento de parámetros de negociación predeterminados. Todas las acciones se mantienen en propiedad directa.

내부자 거래 알림: Insmed의 최고운영책임자(Chief Operating Officer) Roger Adsett가 2025년 6월 16일, 2025년 3월 4일에 설정된 사전 계획된 10b5-1 거래 계획을 통해 대규모 주식 매각을 실행했습니다.

거래 세부사항:

  • 첫 번째 거래: 6,500주를 가중평균 가격 $98.50에 매도 (범위: $97.93-$98.92)
  • 두 번째 거래: 4,186주를 가중평균 가격 $99.32에 매도 (범위: $98.94-$99.83)
  • 총 매도 주식: 10,686주
  • 남은 보유 주식: 직접 보유한 130,637주

이 거래들은 미리 정해진 거래 조건을 설정하여 내부자 거래 혐의로부터 안전한 보호를 제공하는 Rule 10b5-1 거래 계획에 따라 실행되었습니다. 모든 주식은 직접 소유 형태로 보유되고 있습니다.

Alerte sur les Transactions d’Initiés : Roger Adsett, Directeur des Opérations d’Insmed, a réalisé des ventes importantes d’actions le 16 juin 2025, via un plan de trading 10b5-1 préétabli le 4 mars 2025.

Détails des transactions :

  • Première transaction : Vente de 6 500 actions au prix moyen pondéré de 98,50 $ (fourchette : 97,93 $ - 98,92 $)
  • Deuxième transaction : Vente de 4 186 actions au prix moyen pondéré de 99,32 $ (fourchette : 98,94 $ - 99,83 $)
  • Total des actions cédées : 10 686 actions
  • Actions restantes : 130 637 actions détenues en direct

Ces transactions ont été réalisées dans le cadre d’un plan de trading conforme à la règle 10b5-1, qui offre une protection contre les accusations de délit d’initié en établissant des paramètres de trading prédéfinis. Toutes les actions sont détenues en propriété directe.

Insider-Handelswarnung: Roger Adsett, Chief Operating Officer von Insmed, führte am 16. Juni 2025 bedeutende Aktienverkäufe durch, basierend auf einem vorab festgelegten 10b5-1-Handelsplan, der am 4. März 2025 eingerichtet wurde.

Transaktionsdetails:

  • Erste Transaktion: Verkauf von 6.500 Aktien zu einem gewichteten Durchschnittspreis von 98,50 $ (Spanne: 97,93 $–98,92 $)
  • Zweite Transaktion: Verkauf von 4.186 Aktien zu einem gewichteten Durchschnittspreis von 99,32 $ (Spanne: 98,94 $–99,83 $)
  • Gesamt verkaufte Aktien: 10.686 Aktien
  • Verbleibender Bestand: 130.637 Aktien im Direktbesitz

Die Transaktionen erfolgten im Rahmen eines Rule 10b5-1-Handelsplans, der einen sicheren Hafen vor Vorwürfen des Insiderhandels bietet, indem vorab festgelegte Handelsparameter definiert werden. Alle Aktien befinden sich im direkten Eigentum.

Positive
  • None.
Negative
  • None.

Avviso di Insider Trading: Roger Adsett, Chief Operating Officer di Insmed, ha effettuato vendite significative di azioni il 16 giugno 2025, tramite un piano di trading 10b5-1 predefinito stabilito il 4 marzo 2025.

Dettagli della transazione:

  • Prima transazione: Vendute 6.500 azioni a un prezzo medio ponderato di 98,50 $ (intervallo: 97,93 $-98,92 $)
  • Seconda transazione: Vendute 4.186 azioni a un prezzo medio ponderato di 99,32 $ (intervallo: 98,94 $-99,83 $)
  • Totale azioni cedute: 10.686 azioni
  • Azioni rimanenti: 130.637 azioni detenute direttamente

Le operazioni sono state eseguite nell'ambito di un piano di trading conforme alla Regola 10b5-1, che garantisce una protezione legale contro accuse di insider trading definendo parametri di trading predefiniti. Tutte le azioni sono detenute in forma di proprietà diretta.

Alerta de Operaciones con Información Privilegiada: Roger Adsett, Director de Operaciones de Insmed, realizó ventas significativas de acciones el 16 de junio de 2025, a través de un plan de negociación 10b5-1 preestablecido el 4 de marzo de 2025.

Detalles de la transacción:

  • Primera transacción: Vendió 6,500 acciones a un precio promedio ponderado de $98.50 (rango: $97.93-$98.92)
  • Segunda transacción: Vendió 4,186 acciones a un precio promedio ponderado de $99.32 (rango: $98.94-$99.83)
  • Total de acciones vendidas: 10,686 acciones
  • Acciones restantes: 130,637 acciones en propiedad directa

Las transacciones se ejecutaron bajo un plan de negociación conforme a la Regla 10b5-1, que ofrece una protección legal contra acusaciones de uso de información privilegiada mediante el establecimiento de parámetros de negociación predeterminados. Todas las acciones se mantienen en propiedad directa.

내부자 거래 알림: Insmed의 최고운영책임자(Chief Operating Officer) Roger Adsett가 2025년 6월 16일, 2025년 3월 4일에 설정된 사전 계획된 10b5-1 거래 계획을 통해 대규모 주식 매각을 실행했습니다.

거래 세부사항:

  • 첫 번째 거래: 6,500주를 가중평균 가격 $98.50에 매도 (범위: $97.93-$98.92)
  • 두 번째 거래: 4,186주를 가중평균 가격 $99.32에 매도 (범위: $98.94-$99.83)
  • 총 매도 주식: 10,686주
  • 남은 보유 주식: 직접 보유한 130,637주

이 거래들은 미리 정해진 거래 조건을 설정하여 내부자 거래 혐의로부터 안전한 보호를 제공하는 Rule 10b5-1 거래 계획에 따라 실행되었습니다. 모든 주식은 직접 소유 형태로 보유되고 있습니다.

Alerte sur les Transactions d’Initiés : Roger Adsett, Directeur des Opérations d’Insmed, a réalisé des ventes importantes d’actions le 16 juin 2025, via un plan de trading 10b5-1 préétabli le 4 mars 2025.

Détails des transactions :

  • Première transaction : Vente de 6 500 actions au prix moyen pondéré de 98,50 $ (fourchette : 97,93 $ - 98,92 $)
  • Deuxième transaction : Vente de 4 186 actions au prix moyen pondéré de 99,32 $ (fourchette : 98,94 $ - 99,83 $)
  • Total des actions cédées : 10 686 actions
  • Actions restantes : 130 637 actions détenues en direct

Ces transactions ont été réalisées dans le cadre d’un plan de trading conforme à la règle 10b5-1, qui offre une protection contre les accusations de délit d’initié en établissant des paramètres de trading prédéfinis. Toutes les actions sont détenues en propriété directe.

Insider-Handelswarnung: Roger Adsett, Chief Operating Officer von Insmed, führte am 16. Juni 2025 bedeutende Aktienverkäufe durch, basierend auf einem vorab festgelegten 10b5-1-Handelsplan, der am 4. März 2025 eingerichtet wurde.

Transaktionsdetails:

  • Erste Transaktion: Verkauf von 6.500 Aktien zu einem gewichteten Durchschnittspreis von 98,50 $ (Spanne: 97,93 $–98,92 $)
  • Zweite Transaktion: Verkauf von 4.186 Aktien zu einem gewichteten Durchschnittspreis von 99,32 $ (Spanne: 98,94 $–99,83 $)
  • Gesamt verkaufte Aktien: 10.686 Aktien
  • Verbleibender Bestand: 130.637 Aktien im Direktbesitz

Die Transaktionen erfolgten im Rahmen eines Rule 10b5-1-Handelsplans, der einen sicheren Hafen vor Vorwürfen des Insiderhandels bietet, indem vorab festgelegte Handelsparameter definiert werden. Alle Aktien befinden sich im direkten Eigentum.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Adsett Roger

(Last) (First) (Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S(1) 6,500 D $98.5(2) 134,823 D
Common Stock 06/16/2025 S(1) 4,186 D $99.32(3) 130,637 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. This is the weighted average sales price representing 6,500 shares sold at prices ranging from $97.93 to $98.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. This is the weighted average sales price representing 4,186 shares sold at prices ranging from $98.94 to $99.83 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
Remarks:
/s/ Roger Adsett, by Michael A. Smith as Attorney-in-fact 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many INSM shares did COO Roger Adsett sell on June 16, 2025?

COO Roger Adsett sold a total of 10,686 shares of INSM common stock on June 16, 2025, consisting of 6,500 shares at an average price of $98.50 and 4,186 shares at an average price of $99.32.

What was the price range for INSM shares sold by Roger Adsett?

The shares were sold in two tranches with different price ranges: The first 6,500 shares were sold at prices ranging from $97.93 to $98.92 per share, and the second tranche of 4,186 shares were sold at prices ranging from $98.94 to $99.83 per share.

How many INSM shares does Roger Adsett own after the June 16, 2025 transactions?

Following the reported transactions, Roger Adsett directly owns 130,637 shares of INSM common stock.

Was the INSM insider sale part of a pre-planned trading arrangement?

Yes, the transactions were executed pursuant to a Rule 10b5-1 trading plan that Roger Adsett adopted on March 4, 2025, in accordance with Securities Exchange Act regulations.

What is Roger Adsett's position at INSM?

Roger Adsett serves as the Chief Operating Officer (COO) of Insmed Inc.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

19.92B
187.30M
0.98%
112.55%
8.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER